What is SecondWave Systems?
SecondWave Systems is a pioneering medtech enterprise focused on the development of non-invasive, ultrasound-based neuromodulation technologies. The company's core platform is designed to provide physicians and patients with a novel therapeutic alternative for managing complex diseases. By leveraging the precision of ultrasound, SecondWave aims to modulate neural pathways without the need for invasive surgical procedures, thereby addressing significant unmet needs in the current healthcare landscape. The company's technology is positioned to disrupt traditional treatment paradigms by offering a scalable, patient-centric solution that enhances clinical outcomes while potentially reducing the long-term economic burden on healthcare systems.
How much funding has SecondWave Systems raised?
SecondWave Systems has raised a total of $17.4M across 3 funding rounds:
Angel/Seed
$7.4M
Other Financing Round
$3M
Series A
$7M
Angel/Seed (2021): $7.4M with participation from Department of Defense - Defense Advanced Research Projects Agency and U.S. Department of Defense
Other Financing Round (2024): $3M led by Advanced Research Projects Agency for Health and Department of Defense - Defense Advanced Research Projects Agency
Series A (2025): $7M supported by Scientific Health Development, Treo Ventures, Sectoral Asset Management, and Carlson School of Management - University of Minnesota
Key Investors in SecondWave Systems
Scientific Health Development
A Dallas-based venture capital firm established in 2006 that specializes in investing in early-stage medtech companies in the U.S. targeting unmet clinical needs.
Treo Ventures
A capital fund founded in 2018 that focuses on medical device and digital health innovation targeting large unmet healthcare needs.
Sectoral Asset Management
An investment advisor specializing in managing equities globally within the healthcare sector, offering a range of public and private equity strategies.
What's next for SecondWave Systems?
With the successful closure of its Series A round, SecondWave Systems is poised to enter a phase of accelerated clinical execution. The strategic infusion of capital will likely be directed toward expanding human clinical trials, optimizing the wearable form factor of its neuromodulation device, and navigating the regulatory pathways required for market entry. Given the involvement of specialized healthcare venture firms, the company is expected to focus on achieving near-term value inflection points that demonstrate both the safety and efficacy of its ultrasound platform. As the firm scales, it will likely prioritize the development of a robust commercialization strategy, ensuring that its innovative technology can be seamlessly integrated into existing clinical workflows to maximize patient access and therapeutic impact.
See full SecondWave Systems company page
